⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130536 | 0.93 | — | — | |
| SCHEMBL28201993 | 0.86 | — | — | |
| SCHEMBL27999319 | 0.86 | — | — | |
| SCHEMBL28263692 | 0.86 | — | — | |
| SCHEMBL9557582 | 0.86 | ALDH1A1 (0.33) | — | |
| SCHEMBL28873936 | 0.86 | — | — | |
| Ammonia Solution, Strong SCHEMBL5962572 | 0.86 | — | — | |
| SCHEMBL4890100 | 0.86 | — | — | |
| SCHEMBL11427258 | 0.86 | — | — | |
| SCHEMBL27999525 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358929-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-3558318-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| WO-2023158221-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | 주식회사 카나프테라퓨틱스 | 2023-08-24 | — | — | WO | disclosed |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200087323-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-19 | — | — | US | disclosed |
| CN-110300590-A | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-105579444-B | Piperidinylindole derivatives and their use as complement factor B inhibitors | 诺华股份有限公司 | 2018-05-01 | — | — | CN | disclosed |
| CN-107501563-A | A kind of dithionate's functionalization pentaerythrite core star dissaving polymer heavy metal stabilizer | 河南清水源科技股份有限公司 | 2017-12-22 | — | — | CN | disclosed |
| CN-107253933-A | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | 勃林格殷格翰国际有限公司 | 2017-10-17 | — | — | CN | disclosed |
| CN-107226599-A | The preparation method and the recycling processing method of heavy metal sewage sludge of a kind of ferric-polysilicate flocculant using iron content heavy metal sewage sludge as raw material | 环境保护部南京环境科学研究所 | 2017-10-03 | — | — | CN | disclosed |
| CN-106660988-A | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | 勃林格殷格翰国际有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-106458955-A | Aryl substituted heterocyclyl sulfones | 格吕伦塔尔有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106164051-A | Aromatic compounds and application thereof | 住友化学株式会社 | 2016-11-23 | — | — | CN | disclosed |
| CN-104781213-A | Pressure process | WZR ceramic solutions GmbH | 2015-07-15 | — | — | CN | disclosed |
| EP-0797986-B1 | Veterinary compositions containing antibacterials for intramammary use | FATRO SPA (IT) | 2003-01-22 | — | — | EP | disclosed |
| EP-0797986-A1 | Veterinary compositions containing antibacterials for intramammary use | FATRO S.p.A. (IT) | 1997-10-01 | — | — | EP | disclosed |